Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by HeartWare International Inc. (“HeartWare” or the “Company”) (NASDAQ:HTWR). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
If you purchased shares of HeartWare during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
On September 9, 2015, HeartWare announced that it had stopped its MVAD clinical trial to address an MVAD controller manufacturing process problem. On October 13, 2015, HeartWare reported it might not re-initiate enrollment in the MVAD clinical trial in November as it had previously planned.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151029006901/en/
Contacts:
Joon M. Khang, Esq.
Telephone:
949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
